Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 12.22
AGEN's Cash to Debt is ranked lower than
56% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. AGEN: 12.22 )
Ranked among companies with meaningful Cash to Debt only.
AGEN' s 10-Year Cash to Debt Range
Min: 0.24  Med: 1.69 Max: N/A
Current: 12.22
Equity to Asset 0.48
AGEN's Equity to Asset is ranked lower than
72% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AGEN: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
AGEN' s 10-Year Equity to Asset Range
Min: -1.33  Med: -0.08 Max: 0.92
Current: 0.48
-1.33
0.92
F-Score: 4
Z-Score: -2.71
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -566.05
AGEN's Operating margin (%) is ranked lower than
73% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. AGEN: -566.05 )
Ranked among companies with meaningful Operating margin (%) only.
AGEN' s 10-Year Operating margin (%) Range
Min: -11732.38  Med: -1550.48 Max: -42.23
Current: -566.05
-11732.38
-42.23
Net-margin (%) -690.04
AGEN's Net-margin (%) is ranked lower than
75% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. AGEN: -690.04 )
Ranked among companies with meaningful Net-margin (%) only.
AGEN' s 10-Year Net-margin (%) Range
Min: -11762.54  Med: -1388.19 Max: -70.95
Current: -690.04
-11762.54
-70.95
ROE (%) -177.67
AGEN's ROE (%) is ranked lower than
89% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. AGEN: -177.67 )
Ranked among companies with meaningful ROE (%) only.
AGEN' s 10-Year ROE (%) Range
Min: -726.2  Med: -74.54 Max: -53.81
Current: -177.67
-726.2
-53.81
ROA (%) -83.28
AGEN's ROA (%) is ranked lower than
80% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. AGEN: -83.28 )
Ranked among companies with meaningful ROA (%) only.
AGEN' s 10-Year ROA (%) Range
Min: -94.08  Med: -60.78 Max: -41.12
Current: -83.28
-94.08
-41.12
ROC (Joel Greenblatt) (%) -1300.49
AGEN's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. AGEN: -1300.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1025.9  Med: -305.82 Max: -195.97
Current: -1300.49
-1025.9
-195.97
Revenue Growth (3Y)(%) -5.00
AGEN's Revenue Growth (3Y)(%) is ranked lower than
55% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AGEN: -5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -54.7  Med: -5.00 Max: 100
Current: -5
-54.7
100
EBITDA Growth (3Y)(%) -7.70
AGEN's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. AGEN: -7.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -51  Med: -17.20 Max: 17
Current: -7.7
-51
17
EPS Growth (3Y)(%) -16.30
AGEN's EPS Growth (3Y)(%) is ranked lower than
62% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. AGEN: -16.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -40  Med: -16.30 Max: 19.4
Current: -16.3
-40
19.4
» AGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

AGEN Guru Trades in Q3 2014

Robert Bruce 233,515 sh (unchged)
Paul Tudor Jones 11,197 sh (-34.13%)
» More
Q4 2014

AGEN Guru Trades in Q4 2014

Paul Tudor Jones 15,497 sh (+38.40%)
Robert Bruce 233,515 sh (unchged)
» More
Q1 2015

AGEN Guru Trades in Q1 2015

Paul Tudor Jones 29,718 sh (+91.77%)
Robert Bruce 233,515 sh (unchged)
» More
Q2 2015

AGEN Guru Trades in Q2 2015

Jim Simons 167,015 sh (New)
Paul Tudor Jones 33,684 sh (+13.35%)
Robert Bruce 233,515 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.80
AGEN's P/B is ranked lower than
63% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. AGEN: 5.80 )
Ranked among companies with meaningful P/B only.
AGEN' s 10-Year P/B Range
Min: 2.5  Med: 4.80 Max: 37.35
Current: 5.8
2.5
37.35
P/S 37.27
AGEN's P/S is ranked lower than
77% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. AGEN: 37.27 )
Ranked among companies with meaningful P/S only.
AGEN' s 10-Year P/S Range
Min: 4.61  Med: 29.14 Max: 662.4
Current: 37.27
4.61
662.4
Current Ratio 5.78
AGEN's Current Ratio is ranked higher than
59% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. AGEN: 5.78 )
Ranked among companies with meaningful Current Ratio only.
AGEN' s 10-Year Current Ratio Range
Min: 0.64  Med: 4.74 Max: 42.49
Current: 5.78
0.64
42.49
Quick Ratio 5.77
AGEN's Quick Ratio is ranked higher than
60% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. AGEN: 5.77 )
Ranked among companies with meaningful Quick Ratio only.
AGEN' s 10-Year Quick Ratio Range
Min: 0.64  Med: 4.72 Max: 42.49
Current: 5.77
0.64
42.49
Days Sales Outstanding 111.05
AGEN's Days Sales Outstanding is ranked lower than
75% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. AGEN: 111.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGEN' s 10-Year Days Sales Outstanding Range
Min: 0.12  Med: 39.02 Max: 439.15
Current: 111.05
0.12
439.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.17
AGEN's Price/Net Cash is ranked lower than
62% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. AGEN: 11.17 )
Ranked among companies with meaningful Price/Net Cash only.
AGEN' s 10-Year Price/Net Cash Range
Min: 3.44  Med: 6.60 Max: 46.46
Current: 11.17
3.44
46.46
Price/Net Current Asset Value 9.68
AGEN's Price/Net Current Asset Value is ranked lower than
60% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. AGEN: 9.68 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AGEN' s 10-Year Price/Net Current Asset Value Range
Min: 3.28  Med: 6.22 Max: 25.65
Current: 9.68
3.28
25.65
Price/Tangible Book 8.44
AGEN's Price/Tangible Book is ranked lower than
67% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. AGEN: 8.44 )
Ranked among companies with meaningful Price/Tangible Book only.
AGEN' s 10-Year Price/Tangible Book Range
Min: 2.28  Med: 4.48 Max: 17.1
Current: 8.44
2.28
17.1
Price/Median PS Value 1.31
AGEN's Price/Median PS Value is ranked lower than
62% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. AGEN: 1.31 )
Ranked among companies with meaningful Price/Median PS Value only.
AGEN' s 10-Year Price/Median PS Value Range
Min: 0.2  Med: 1.21 Max: 117.31
Current: 1.31
0.2
117.31
Earnings Yield (Greenblatt) (%) -15.91
AGEN's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. AGEN: -15.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGEN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -17.83  Med: 0.00 Max: 0
Current: -15.91
-17.83
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 29 29 38
EPS($) -0.69 -0.67 -0.64
EPS without NRI($) -0.69 -0.67 -0.64

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AJ81.Germany,
Agenus Inc formerly known as Antigenics Inc was incorporated in 1994. The Company, along with its subsidiaries, is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein vaccines and adjuvants. It is focused on immunotherapeutic products based on core platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Its core technology portfolio consists of Heat Shock Protein Platform, and Saponin Platform. Within HSP Platform the Company is developing its Prophage Series cancer vaccines and Recombinant Series. In Prophage Series the Company has tested product candidates in Phase 3 clinical trials for the treatment of renal cell carcinoma, the common type of kidney cancer, and for metastatic melanoma, as well as in Phase 1 and Phase 2 clinical trials. In addition, the Cancer Therapy Evaluation Program of the National Cancer Institute opened patient enrollment in 2013 for a 222-patient, multi-center, randomized Phase 2 trial of Prophage Series vaccine G-200 in combination with Avastin in patients with surgically resectable recurrent glioma. HerpV, a therapeutic vaccine candidate from the Recombinant Series which contains QS-21 Stimulon, has been tested in a Phase 1 clinical trial for the treatment of genital herpes and is now in a Phase 2 trial. Within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by licensees in numerous vaccines under development in trials, some as advanced as Phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus, and tuberculosis. The Company's business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of its collaborations. The Company faces intense competition from pharmaceutical companies and specialized biotechnology companies that market products or that are engaged in the development of product candidates directed at cancer, infectious diseases and degenerative disorders. Several of these companies have products that utilize similar technologies and patient-specific medicine techniques. The Company is also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act and the Resource Conservation and Recovery Act, and other current and potential future federal, state, or local regulations.
» More Articles for AGEN

Headlines

Articles On GuruFocus.com
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
rusty Jan 26 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
Agenus: Grossly Undervalued GlaxoSmithKline Acquisition Target Sep 10 2012 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 

More From Other Websites
Checkmate Pharma is latest cancer drug firm focused on immune system (BBJ photo gallery) Aug 12 2015
AGENUS INC Financials Aug 08 2015
10-Q for Agenus, Inc. Aug 05 2015
Edited Transcript of AGEN earnings conference call or presentation 23-Jul-15 3:00pm GMT Jul 24 2015
Malaria vaccine moves toward approval with Lexington biotech's help Jul 24 2015
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 24 2015
UPDATE 1-World's first malaria vaccine gets go-ahead from EU regulators Jul 24 2015
GSK’s Malaria Vaccine Containing Agenus’ QS-21 Stimulon® Receives Positive Opinion from... Jul 24 2015
Agenus (AGEN) Reports Wider-than-Expected Q2 Loss - Tale of the Tape Jul 23 2015
Agenus reports 2Q loss Jul 23 2015
Agenus reports 2Q loss Jul 23 2015
Q2 2015 Agenus Inc Earnings Release - Before Market Open Jul 23 2015
AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 23 2015
Agenus Reports Second Quarter 2015 Financial Results Jul 23 2015
Will Agenus (AGEN) Disappoint Investors this Earnings? - Analyst Blog Jul 21 2015
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 20 2015
Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1 Jul 20 2015
Agenus to Report Second Quarter 2015 Financial Results on July 23, 2015; Conference Call to Follow Jul 16 2015
Did Anyone Notice Sucampo's Breakout? Jul 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK